About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(tetO-MYC)36aBop
transgene insertion 36a, J Michael Bishop
MGI:3039697
Summary 5 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Rb1tm3Tyj/Rb1tm3Tyj
Tg(tetO-MYC)36aBop/0
Tg(Cebpb-tTA)5Bjd/0
involves: FVB/N * NMRI MGI:5008419
cx2
Trp53bp2tm1Cdlo/Trp53bp2+
Tg(EmuSR-tTa)83Bop/0
Tg(tetO-MYC)36aBop/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N MGI:3839868
cx3
Tg(Pax8-rtTA2S*M2)1Koes/0
Tg(tetO-MYC)36aBop/0
involves: C57BL/6 * DBA * FVB/N MGI:3815300
cx4
Tg(Ggt1-tTA)#Agoc/0
Tg(tetO-MYC)36aBop/0
involves: FVB/N MGI:5705536
cx5
Tg(tetO-MYC)36aBop/0
Tg(Cebpb-tTA)5Bjd/0
involves: FVB/N * NMRI MGI:4358091


Genotype
MGI:5008419
cn1
Allelic
Composition
Rb1tm3Tyj/Rb1tm3Tyj
Tg(tetO-MYC)36aBop/0
Tg(Cebpb-tTA)5Bjd/0
Genetic
Background
involves: FVB/N * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rb1tm3Tyj mutation (1 available); any Rb1 mutation (34 available)
Tg(Cebpb-tTA)5Bjd mutation (3 available)
Tg(tetO-MYC)36aBop mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase, adult liver cells exhibit an increase in polyploidy (J:172430)
• following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase, adult liver cells exhibit an increase in polyploidy (J:172430)

mortality/aging
• median survival of mutants is 27 weeks following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase (J:172430)
• median survival of mutants with tumors is 16.5 weeks following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase (J:172430)
• median survival of mutants is 27 weeks following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase (J:172430)
• median survival of mutants with tumors is 16.5 weeks following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase (J:172430)

tumorigenesis
• following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase, some mice develop liver tumors composed of multiple fleshy vascular nodules (J:172430)
• following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase, some mice develop liver tumors composed of multiple fleshy vascular nodules (J:172430)
• tumors of mice injected with adenovirus expressing Cre recombinase and without doxycycline to induce MYC expression are composed of hepatocellular neoplasms characterized by sheets of cells with occasional mitotic figure, slightly pleomorphic nuclei, and prominent nucleoli (J:172430)
• tumors show a range of differentiation between well- and moderately-differentiated hepatocellular carcinoma (J:172430)
• tumors of mice injected with adenovirus expressing Cre recombinase and without doxycycline to induce MYC expression are composed of hepatocellular neoplasms characterized by sheets of cells with occasional mitotic figure, slightly pleomorphic nuclei, and prominent nucleoli (J:172430)
• tumors show a range of differentiation between well- and moderately-differentiated hepatocellular carcinoma (J:172430)

Mouse Models of Human Disease
OMIM ID Ref(s)
Hepatocellular Carcinoma 114550 J:172430




Genotype
MGI:3839868
cx2
Allelic
Composition
Trp53bp2tm1Cdlo/Trp53bp2+
Tg(EmuSR-tTa)83Bop/0
Tg(tetO-MYC)36aBop/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(EmuSR-tTa)83Bop mutation (0 available)
Tg(tetO-MYC)36aBop mutation (1 available)
Trp53bp2tm1Cdlo mutation (1 available); any Trp53bp2 mutation (8 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• incidence of T cell lymphomas is similar to that in transgenic mice wild-type for Trp53bp2 (J:146764)
• incidence of T cell lymphomas is similar to that in transgenic mice wild-type for Trp53bp2 (J:146764)




Genotype
MGI:3815300
cx3
Allelic
Composition
Tg(Pax8-rtTA2S*M2)1Koes/0
Tg(tetO-MYC)36aBop/0
Genetic
Background
involves: C57BL/6 * DBA * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Pax8-rtTA2S*M2)1Koes mutation (2 available)
Tg(tetO-MYC)36aBop mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
renal/urinary system
• following induction with doxycycline, mice develop glomerular cysts (J:140925)
• following induction with doxycycline, mice develop glomerular cysts (J:140925)
• following induction with doxycycline, mice develop multiple renal cysts in all renal tubular compartments (J:140925)
• following induction with doxycycline, mice develop multiple renal cysts in all renal tubular compartments (J:140925)
• 3 to 4 months following induction with doxycycline (J:140925)
• 3 to 4 months following induction with doxycycline (J:140925)

tumorigenesis
• following induction with doxycycline, mice develop renal adenomas (J:140925)
• following induction with doxycycline, mice develop renal adenomas (J:140925)
• following induction with doxycycline (J:140925)
• following induction with doxycycline (J:140925)




Genotype
MGI:5705536
cx4
Allelic
Composition
Tg(Ggt1-tTA)#Agoc/0
Tg(tetO-MYC)36aBop/0
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Ggt1-tTA)#Agoc mutation (0 available)
Tg(tetO-MYC)36aBop mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
renal/urinary system
• removal of doxycycline (dox) results in increased kidney size (J:222943)
• removal of doxycycline (dox) results in increased kidney size (J:222943)

tumorigenesis
• removal of dox results in the development of rapidly progressing of renal cell carcinoma (J:222943)
• marker analysis indicates that tumor subtype is of the collecting-duct carcinoma which exhibits a distinct lipid signature (J:222943)
• treatment with dox reverses tumor and results in regression of the renal cell carcinoma (J:222943)
• initiation of renal cell carcinoma is associated with the activation of glutaminolysis (J:222943)
• treatment with dox to suppress MYC protein expression results in regression of the renal cell carcinoma due to inhibition of proliferation accompanied by the persistence of apoptosis (J:222943)
• treatment with an inhibitor of kidney type glutaminase BPTES slows progression of renal cell carcinoma tumors, reduces neoplastic cells, and decreases kidney cell proliferation (J:222943)
• removal of dox results in the development of rapidly progressing of renal cell carcinoma (J:222943)
• marker analysis indicates that tumor subtype is of the collecting-duct carcinoma which exhibits a distinct lipid signature (J:222943)
• treatment with dox reverses tumor and results in regression of the renal cell carcinoma (J:222943)
• initiation of renal cell carcinoma is associated with the activation of glutaminolysis (J:222943)
• treatment with dox to suppress MYC protein expression results in regression of the renal cell carcinoma due to inhibition of proliferation accompanied by the persistence of apoptosis (J:222943)
• treatment with an inhibitor of kidney type glutaminase BPTES slows progression of renal cell carcinoma tumors, reduces neoplastic cells, and decreases kidney cell proliferation (J:222943)




Genotype
MGI:4358091
cx5
Allelic
Composition
Tg(tetO-MYC)36aBop/0
Tg(Cebpb-tTA)5Bjd/0
Genetic
Background
involves: FVB/N * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Cebpb-tTA)5Bjd mutation (3 available)
Tg(tetO-MYC)36aBop mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• following withdrawal of doxycycline, all mice succumb to liver tumors within 2 weeks (J:93899)
• following withdrawal of doxycycline, all mice succumb to liver tumors within 2 weeks (J:93899)
• median survival of mutants is 31 weeks following doxycycline withdrawal to induce MYC expression (J:172430)
• median survival of mutants with tumors is 27 weeks following doxycycline withdrawal to induce MYC expression (J:172430)
• median survival of mutants is 31 weeks following doxycycline withdrawal to induce MYC expression (J:172430)
• median survival of mutants with tumors is 27 weeks following doxycycline withdrawal to induce MYC expression (J:172430)

tumorigenesis
• doxycycline-treated mice infected with an adeno-associated virus-expressing Mir122 exhibit suppression of tumorigenesis tumor cell proliferation compared with control mice (J:190067)
• doxycycline-treated mice infected with an adeno-associated virus-expressing Mir122 exhibit suppression of tumorigenesis tumor cell proliferation compared with control mice (J:190067)
• following withdrawal of doxycycline, mice develop tumors with a latency of 12 weeks and all mice succumb to liver tumors within 2 weeks (J:93899)
• liver tumors that develop in mice after doxycycline withdrawal are invasive and metastasis into the thoracic cavity and lung parenchyma (J:93899)
• however, re-establishment of doxycycline-treatment produces rapid and sustained tumor regression (J:93899)
• repeated withdrawal and treatment with doxycyclineinduces and represses, respectively, tumor formation (J:93899)
• following withdrawal of doxycycline, mice develop tumors with a latency of 12 weeks and all mice succumb to liver tumors within 2 weeks (J:93899)
• liver tumors that develop in mice after doxycycline withdrawal are invasive and metastasis into the thoracic cavity and lung parenchyma (J:93899)
• however, re-establishment of doxycycline-treatment produces rapid and sustained tumor regression (J:93899)
• repeated withdrawal and treatment with doxycyclineinduces and represses, respectively, tumor formation (J:93899)
• liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas (J:93899)
• liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas (J:93899)
• liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas (J:93899)
• liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas (J:93899)
• tumors that form in mice after doxycycline withdrawal are composed of hepatocellular neoplasms characterized by sheets of cells with occasional mitotic figure, slightly pleomorphic nuclei, and prominent nucleoli (J:172430)
• tumors show a range of differentiation between well- and moderately-differentiated hepatocellular carcinoma (J:172430)
• tumors that form in mice after doxycycline withdrawal are composed of hepatocellular neoplasms characterized by sheets of cells with occasional mitotic figure, slightly pleomorphic nuclei, and prominent nucleoli (J:172430)
• tumors show a range of differentiation between well- and moderately-differentiated hepatocellular carcinoma (J:172430)
• in doxycycline-treated mice (J:190067)
• however, treatment with adeno-associated virus-expressing Mir122 suppresses tumorigenesis (J:190067)
• in doxycycline-treated mice (J:190067)
• however, treatment with adeno-associated virus-expressing Mir122 suppresses tumorigenesis (J:190067)

Mouse Models of Human Disease
OMIM ID Ref(s)
Colorectal Cancer; CRC 114500 J:190067
Hepatocellular Carcinoma 114550 J:93899 , J:172430





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory